DanielRobtBudmanMD

PubMed

• 3 citations
  The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
  Cristina Ghiuzeli, Miroslav Stýblo, Jesse Saunders, Anthony Calabro, Daniel R. Budman, Steven L. Allen, Craig Devoe, Radhika Dhingra> ;Leukemia & Lymphoma. 2021 Oct 25
• 2 citations
  Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).
  Dyda Dao, Tyler Zemla, Aminah Jatoi, Rachel A. Freedman, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Lawrence N. Shulman, Marc L. Citron, Daniel R. Budman, Ryan McMur...> ;The Oncologist. 2019 Jun 1
• 98 citations
  Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
  Karie Runcie, Daniel R. Budman, Veena S. John, Nagashree Seetharamu> ;Molecular Medicine. 2018 Sep 24
• 4 citations
  Immune checkpoint inhibitors in lung cancer: an update.
  Kevin M. Sullivan, Isabel Ruth Preeshagul, Daniel R. Budman, Nagashree Seetharamu> ;Future Oncology. 2017 May 8
• 26 citations
  Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
  Kelly-Anne Phillips, Meredith M. Regan, Karin Ribi, Prudence A. Francis, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R. Budman, Khalil Zaman...> ;British Journal of Cancer. 2016 Apr 26
• 23 citations
  Immune checkpoint inhibitors in lung cancer: past, present and future
  Nagashree Seetharamu, Daniel R. Budman, Kevin M. Sullivan> ;Future Oncology. 2016 Mar 29
• 124 citations
  Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
  Iuliana Shapira, Michaela Oswald, J.L. Lovecchio, Houman Khalili, A.W. Menzin, J.S. Whyte, L. Dos Santos, Sharron Liang, Tawfiqul Bhuiya, Mary Keogh, C. Mason, Keith S...> ;British Journal of Cancer. 2014 Feb 18
• 51 citations
  Profile of panobinostat and its potential for treatment in solid tumors: an update.
  Madhurima Anne, Daniel Sammartino, Myra F. Barginear, Daniel R. Budman> ;Oncotargets and Therapy. 2013 Nov 15
• 27 citations
  P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
  Iuliana Shapira, Annette Lee, Reena K. Vora, Daniel R. Budman> ;Critical Reviews in Oncology/hematology. 2013 Nov 1
• 1 citations
  Integrating Molecular Biology Into Clinical Practice
  Myra F. Barginear, Daniel R. Budman> ;Journal of Clinical Oncology. 2013 May 6
• 26 citations
  The evolving use of arsenic in pharmacotherapy of malignant disease.
  Athena Kritharis, Thomas Bradley, Daniel R. Budman> ;Annals of Hematology. 2013 Mar 15
• 10 citations
  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
  Daniel R. Budman, Anthony Calabro, Lisa Rosen, Martin Lesser> ;Anti-Cancer Drugs. 2012 Mar 1
• 38 citations
  Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
  Myra F. Barginear, Veena S. John, Daniel R. Budman> ;Molecular Medicine. 2012 Nov 1
• 64 citations
  Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective ...
  Myra F. Barginear, Richard J. Gralla, Thomas Bradley, Syed S. Ali, Iuliana Shapira, Craig Greben, Nanette Nier-Shoulson, Meredith Akerman, Martin Lesser, Daniel R. Budman> ;Supportive Care in Cancer. 2012 Mar 16
• Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL).
  Kritharis A, Bradley TP, Budman DR> ;J. Clin. Oncol.. 2011-05-20
• Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer.
  Budman DR, Barginear MF, Gralla RJ, Bradley TP, Shapira I, Nier-Shoulson NJ, Greben CR, Akerman M, Lesser M> ;J. Clin. Oncol.. 2011-05-20
• Is there an advantage to adding inferior vena cava filter (IVCF) placement to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE):...
  Barginear MF, Gralla RJ, Akerman M, Lesser M, Bradley TP, Shapira I, Nier-Shoulson NJ, Greben CR, Budman DR> ;J. Clin. Oncol.. 2011-05-20
• 40 citations
  Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
  Mary Leung, David B. Rosen, Scott Fields, Alessandra Cesano, Daniel R Budman> ;Molecular Medicine. 2011 Jan 1
• 1 citations
  Emerging role of small ribonucleic acids in gastrointestinal tumors.
  Iuliana Shapira, Keith Sultan, B. Mehrotra, Daniel R. Budman> ;Critical Reviews in Oncology/hematology. 2010 Dec 1
• 21 citations
  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
  Daniel R. Budman, Julia Tai, Anthony Calabro, Veena John> ;Investigational New Drugs. 2011 Dec 1
• 9 citations
  Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia
  Steven L. Allen, Jonathan E. Kolitz, Ante Sven Lundberg, John M. Bennett, Robert L. Capizzi, Daniel R. Budman> ;Leukemia Research. 2010 Apr 1
• 41 citations
  Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cance...
  Lyndsay Harris, Gloria Broadwater, Maysa M. Abu-Khalaf, David Cowan, Ann D. Thor, Daniel R. Budman, Constance Cirrincione, Donald A. Berry, Eric P. Winer, Clifford A. ...> ;Journal of Clinical Oncology. 2009 Jul 20
• 24 citations
  Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome.
  Myra F. Barginear, Martin Lesser, Meredith Akerman, Marianna Strakhan, Iuliana Shapira, Thomas Bradley, Daniel R. Budman> ;Clinical and Applied Thrombosis/hemostasis. 2009 Jun 1
• 18 citations
  The hedgehog pathway as a therapeutic target for treatment of breast cancer.
  M. F. Barginear, M. Leung, Daniel R. Budman> ;Breast Cancer Research and Treatment. 2009 May 29
• Determining the preferred dose of the serotonin antagonist (5-HT3) palonosetron: Results of an individual patient data meta-analysis (MA) of 1,947 patients in all rand...
  Lesser M, Gralla R, Napolitano B, Raftopoulos H, Kline M, Bria E, Budman DR> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all